FDA Draft Guidance Instructs Sponsors on Content and Timing of Diversity Plans for Clinical Trials | Troutman Pepper
For several years, FDA has advanced a policy of increasing diversity in clinical trial populations. During that time, FDA issued broad policy statements, as well as guidance on improved...
Source: jdsupra.com